CoChat

Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling

Mirzaie, Mehdi, Gholizadeh, Elham, Miettinen, Juho J., Ianevski, Filipp, Ruokoranta, Tanja, Saarela, Jani, Manninen, Mikko, Miettinen, Susanna, Heckman, Caroline A., Jafari, Mohieddin · 2024 · Oncogenesis

Published version of a preprint

Cited by 20

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Acute myeloid leukemia (AML), a heterogeneous and aggressive blood cancer, does not respond well to single-drug therapy. A combination of drugs is required to effectively treat this disease. Computational models are critical for combination therapy discovery due to the tens of thousands of two-drug combinations, even with approved drugs. While predicting synergistic drugs is the focus of current methods, few consider drug efficacy and potential toxicity, which are crucial for treatment success. To find effective new drug candidates, we constructed a bipartite network using patient-derived tumor samples and drugs. The network is based on drug-response screening and summarizes all treatment response heterogeneity as drug response weights. This bipartite network is then projected onto the drug part, resulting in the drug similarity network. Distinct drug clusters were identified using community detection methods, each targeting different biological processes and pathways as revealed by enrichment and pathway analysis of the drugs’ protein targets. Four drugs with the highest efficacy and lowest toxicity from each cluster were selected and tested for drug sensitivity using cell viability assays on various samples. Results show that ruxolitinib-ulixertinib and sapanisertib-LY3009120 are the most effective combinations with the least toxicity and the best synergistic effect on blast cells. These findings lay the foundation for personalized and successful AML therapies, ultimately leading to the development of drug combinations that can be used alongside standard first-line AML treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41389-024-00510-9

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 62

  1. Grzywa TM, Paskal W, Wodarski PK. Intratumor and intertumor heterogeneity in melanoma. Transl Oncol. 2017;10:956–75. · DOI · Paper page
  2. Bennett JM, Catovsky D, Daniel M-T, Flandrin G, Galton DAG, Gralnick HR, et al. Proposals for the classification of the acute leukaemias French-American-British (FAB) co-operative group. Br J Haematol. 1976;33:451–8. · DOI · Paper page
  3. Peipert JD, Efficace F, Pierson R, Loefgren C, Cella D, He J. Patient-reported outcomes predict overall survival in older patients with acute myeloid leukemia. J Geriatr Oncol. 2022;13:935–9. · doi:10.1016/j.jgo.2021.09.007
  4. Daver N, Wei AH, Pollyea DA, Fathi AT, Vyas P, DiNardo CD. New directions for emerging therapies in acute myeloid leukemia: the next chapter. Blood Cancer J. 2020;10:1–12. · DOI · Paper page
  5. Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, et al. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations. Nature. 2018;559:125–29. · DOI · Paper page
  6. Ianevski A, Lahtela J, Javarappa KK, Sergeev P, Ghimire BR, Gautam P, et al. Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. Sci Adv. 2021;7:eabe4038. · DOI
  7. Jafari M, Mirzaie M, Bao J, Barneh F, Zheng S, Eriksson J, et al. Bipartite network models to design combination therapies in acute myeloid leukaemia. Nat Commun. 2022;13:1–12. · DOI
  8. Sarma A, Hazarika M, Das D, Kumar Rai A, Sharma JD, Bhuyan C, et al. Expression of aberrant CD markers in acute leukemia: A study of 100 cases with immunophenotyping by multiparameter flowcytometry. Cancer Biomark. 2015;15:501–5. · doi:10.3233/cbm-150482
  9. Jafari M, Chen C, Mirzaie M, Tang J. NIMAA: an R/CRAN package to accomplish NomInal data Mining AnAlysis. bioRxiv https://doi.org/10.1101/2022.01.13.475835 (2022). · DOI
  10. Blondel VD, Guillaume J-L, Lambiotte R, Lefebvre E. Fast unfolding of communities in large networks. J Stat Mech: Theory Exp. 2008;2008:P10008. · DOI · Paper page
  11. Tang J, Ravikumar B, Alam Z, Rebane A, Vh-Koskela M, Peddinti G, et al. Drug target commons: a community effort to build a consensus knowledge base for drug-target interactions. Cell Chem Biol. 2018;25:224–9. · DOI · Paper page
  12. Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation. 2021;2:100141.
  13. Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020;36:2628–9. · DOI · Paper page
  14. Supek F, Bošnjak M, Škunca N, Šmuc T. REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS ONE. 2011;6:e21800. · DOI · Paper page
  15. Bajusz D, Rcz A, Hberger K. Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J Cheminform. 2015;7:1–13. · DOI · Paper page
  16. Guha R. Chemical informatics functionality in R. J Stat Softw. 2007;18:1–16. · DOI · Paper page
  17. Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41:93–141.
  18. Bliss CI. The toxicity of poisons applied jointly 1. Ann Appl Biol. 1939;26:585–615. · DOI · Paper page
  19. Loewe S. The problem of synergism and antagonism of combined drugs. Arzneimittelforschung. 1953;3:285–90.
  20. Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid-and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci USA. 2017;114:E7554–E7563. · DOI · Paper page
  21. Ianevski A, Giri, AK, Aittokallio, T. SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples. Nucleic Acids Res. 2022;50:W739–W743. · DOI · Paper page
  22. Park J, Park H, Byun JM, Hong J, Shin D-Y, Koh Y, et al. Pan‑RAF inhibitor LY3009120 is highly synergistic with low‑dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations. Oncol Lett. 2021;22:1–11. · DOI
  23. Klein K, Stoiber D, Sexl V, Witalisz-Siepracka A. Untwining anti-tumor and immunosuppressive effects of JAK inhibitors—a strategy for hematological malignancies? Cancers. 2021;13:2611. · DOI
  24. Gilan O, Rioja I, Knezevic K, Bell MJ, Yeung MM, Harker NR, et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science. 2020;368:387–94. · DOI · Paper page
  25. Albertini V, Jain A, Vignati S, Napoli S, Rinaldi A, Kwee I, et al. Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer Streptomyces argillaceus exhibits improved transcriptional repressor activity: implications for cancer therapy. Nucleic Acids Res. 2006;34:1721–34. · DOI
  26. Blanco-Aparicio C, Carnero A. Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol. 2013;85:629–43. · DOI
  27. Hayes TK, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of RAS mutant cancers. Ras Superfamily Small G Proteins: Biology and Mechanisms 1: General Features, Signaling, 135-56 (2014). · DOI
  28. Shimizu T, Kuboki Y, Lin C-C, Yonemori K, Yanai T, Faller DV, et al. A phase 1 study of Sapanisertib (TAK-228) in East Asian patients with advanced nonhematological malignancies. Targeted Oncol. 2022;1–10. · doi:10.1007/s11523-021-00855-w
  29. Economides MP, McCue D, Borthakur G, Pemmaraju N. Topoisomerase II inhibitors in AML: past, present, and future. Expert Opin Pharmacother. 2019;20:1637–44. · DOI
  30. Skuta C, Popr M, Muller T, Jindrich J, Kahle M, Sedlak D, et al. Probes & drugs portal: an interactive, open data resource for chemical biology. Nat Methods. 2017;14:759–60. · DOI
  31. Ferrajoli A, Faderl S, Ravandi F, Estrov Z. The JAK-STAT pathway: a therapeutic target in hematological malignancies. Curr Cancer Drug Targets. 2006;6:671–9. · DOI · Paper page
  32. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood J Am Soc Hematol. 2012;119:4614–8.
  33. Borate U, Saultz JN, Kaempf A, Minnier J, Tognon CE, Kurtz SE, et al. Novel combination therapy of venetoclax and ruxolitinib in the treatment of patients with relapsed/refractory acute myeloid leukemia. Blood. 2021;138:2333. · doi:10.1182/blood-2021-152903
  34. Verbeke D, Gielen O, Jacobs K, Boeckx N, De Keersmaecker K, Maertens J, et al. Ruxolitinib synergizes with dexamethasone for the treatment of T-cell acute lymphoblastic leukemia. Hemasphere 2019;3:e310. https://doi.org/10.1097/HS9.0000000000000310. · DOI
  35. Dal Bello R, Pasanisi J, Joudinaud R, Duchmann M, Pardieu B, Ayaka P, et al. A multiparametric niche-like drug screening platform in acute myeloid leukemia. Blood Cancer J. 2022;12:1–12. · DOI
  36. Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood J Am Soc Hematol. 2017;130:789–802.
  37. Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep. 2014;4:5193. · DOI · Paper page
  38. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N. Engl J Med. 2016;374:2209–21. · DOI · Paper page
  39. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562:526–31. · DOI · Paper page
  40. Rausch C, Rothenberg-Thurley M, Dufour AM, Schneider S, Gittinger H, Sauerland MC, et al. Validation of the 2022 European Leukemianet genetic risk stratification of acute myeloid leukemia. Blood. 2022;140:3408–9. · doi:10.1182/blood-2022-167022
  41. Hasserjian RP. Controversies in the recent (2016) World Health Organization classification of acute myeloid leukemia. Best Pract Res Clin Haematol. 2021;34:101249. · DOI
  42. Medeiros BC. Interpretation of clinical endpoints in trials of acute myeloid leukemia. Leuk Res. 2018;68:32–9. · DOI
  43. Dry JR, Yang M, Saez-Rodriguez J. Looking beyond the cancer cell for effective drug combinations. Genome Med. 2016;8:1–13. · DOI
  44. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: a brief review. Adv Pharm Bull. 2017;7:339. · DOI · Paper page
  45. Xia X. Drug efficacy and toxicity prediction: an innovative application of transcriptomic data. Cell Biol Toxicol. 2020;36:591–602. · DOI
  46. Ling A, Huang RS. Computationally predicting clinical drug combination efficacy with cancer cell line screens and independent drug action. Nat Commun. 2020;11:5848. · DOI
  47. Ricciardi MR, McQueen T, Chism D, Milella M, Estey E, Kaldjian E, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Leukemia. 2005;19:1543–9. · DOI
  48. Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bsecke J, et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia. 2011;25:1080–94. · DOI · Paper page
  49. Chang, F, Steelman, LS, Lee, JT, Shelton, JG, Navolanic, PM, Blalock, WL et al. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia. 2003;17:1263–93. · DOI · Paper page
  50. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108:2358–65. · DOI · Paper page
  51. Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: Mission possible? Nat Rev Drug Discov. 2014;13:828–51. · DOI · Paper page
  52. Tambe M, Karjalainen E, Vh-Koskela M, Bulanova D, Gjertsen BT, Kontro M, et al. Pan-RAF inhibition induces apoptosis in acute myeloid leukemia cells and synergizes with BCL2 inhibition. Leukemia. 2020;34:3186–96. · DOI
  53. Khoury JD, Tashakori M, Yang H, Loghavi S, Wang Y, Wang J, et al. Pan-RAF inhibition shows anti-leukemic activity in RAS-mutant acute myeloid leukemia cells and potentiates the effect of sorafenib in cells with FLT3 mutation. Cancers. 2020;12:3511. · DOI
  54. Park J, Park H, Byun JM, Hong J, Shin D-Y, Koh Y, et al. Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations. Oncol Lett. 2021;22:1–11. · DOI
  55. FDA Updates Highlighting the Latest Cancer Treatments. Oncology Times. 2019;41:36–7. https://doi.org/10.1097/01.COT.0000557874.12684.64. · DOI
  56. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–310. · DOI · Paper page
  57. Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, et al. ERK inhibitor LY3214996 targets ERK pathway-driven cancers: a therapeutic approach toward precision medicine. Mol Cancer Ther. 2020;19:325–36. · DOI · Paper page
  58. Ihle JN, Kerr IM. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet. 1995;11:69–74. · DOI · Paper page
  59. Lin TS, Mahajan S, Frank DA. STAT signaling in the pathogenesis and treatment of leukemias. Oncogene. 2000;19:2496–504. · DOI · Paper page
  60. Furqan M, Mukhi N, Lee B, Liu D. Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application. Biomark Res. 2013;1:1–10. · DOI · Paper page
  61. McKeage K. Ruxolitinib: a review in polycythaemia vera. Drugs. 2015;75:1773–1781. · DOI
  62. Tannock IF, Hickman JA. Molecular screening to select therapy for advanced cancer? Ann Oncol. 2019;30:661–3. · DOI

Cited by

See all 20

Metadata

Authors
Mirzaie, M., Gholizadeh, E., Miettinen, J. J., Ianevski, F., Ruokoranta, T., Saarela, J., Manninen, M., Miettinen, S., Heckman, C. A., & Jafari, M.
Venue
Oncogenesis
Published
2024-03-01
Volume
13
Issue
1
ISSN
2157-9024
Cited by
20
References
8
Language
en
Licence
Funders
  • Academy of Finland (332454, 320185, 334781, 357686)
  • Jane ja Aatos Erkon Säätiö (220031)
  • Sigrid Juséliuksen Säätiö

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling. https://app.cochat.ai/papers/10.1038/s41389-024-00510-9
The paper
Mirzaie, M., Gholizadeh, E., Miettinen, J. J., Ianevski, F., Ruokoranta, T., Saarela, J., Manninen, M., Miettinen, S., Heckman, C. A., & Jafari, M. (2024). Designing patient-oriented combination therapies for acute myeloid leukemia based on efficacy/toxicity integration and bipartite network modeling. Oncogenesis. https://doi.org/10.1038/s41389-024-00510-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.